European Journal of Biomedical and Pharmaceutical Sciences

IMMUNOHISTOCHEMICAL EXPRESSION OF CDX2AMONG SUDANESE PATIENTS WITH CLCORECTAL ADENOCARCINOMA

*Nancy Hassan Abd Elhamid Bakri, Ageeb Mohammed Hassan

ABSTRACT

Colorectal cancer is the fourth most common cancer in the world with approximately 875.000 new cases per year in the worldwide accounting for 8.5% of all new cancer. This study was aimed to detect CDX2 expression among Sudanese patients with colorectal cancer. This study was conducted at Soba University Hospital during the period (June 2018 to November 2019). Forty samples of paraffin wax blocks from patient diagnosed as colorectal carcinoma collected in tissue micro-array slide. The study was used a standard avidin- biotin- peroxidase complex method with monoclonal antibodies against CDX2 for its detection. SPSS version 21 was used to analyze the data. The age range was from 31-80 years old with mean of 55 years old and was devided into two groups less than 40 years old and more than 40 years old. Association between age group and CDX2 expression, showed that (33.3%) had presence of CDX2 and 4(14.3%) had absent of CDX2 among less 40 years old while (66.7%) had present of CDX2 and (85.7%) had absent of CDX2 among more than 40 years old. There was no significant difference in proportion between the two groups. Association between gender of patient and CDX2expression, the showed that male (12.5%) had present of CDX2 and (45.5%) had absent of CDX2, and show female (17.5%) had present of CDX2 and (25.0%) absent of CDX2.Association between stage of the disease and CDX2 expression, (30.8%) of C colorectal cancer patients in stage C had present of CDX2 and (69.2%) of them had absent of CDX2, while (28.6%) of colorectal cancer patients in stage D had present of CDX2 and (71.4%) of them had absent of CDX2. Conclusion: in this study showed CDX2 expresses in patients less than 40years with colorectal adenocarcinoma less than patients above 40years, in female more than male and expresses in stage C more than stage D.

Keywords: Colorectal cancer, CDX2.